Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

64.49 -1.57 (-2.38%)
Official Closing Price Updated: 7:00 PM EDT, Apr 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,944,916
Open 65.64
Bid (Size) 64.53 (1)
Ask (Size) 64.65 (5)
Prev. Close 66.06
Today's Range 63.86 - 65.95
52wk Range 59.32 - 148.15
Shares Outstanding N/A
Dividend Yield 1.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts
FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility. 
Via Benzinga
Topics Economy
Exposures Product Safety Supply Chain
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential. 
Via Benzinga

Performance

YTD
-26.3%
-26.3%
1 Month
-19.5%
-19.5%
3 Month
-23.8%
-23.8%
6 Month
-46.2%
-46.2%
1 Year
-47.9%
-47.9%

More News

Read More
Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch
Via Benzinga
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved
Via Stocktwits
Topics Economy
Exposures Product Safety Supply Chain
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Via The Motley Fool
Recent Filing Shows That Rep. Scott Franklin Bought Over $16K Worth of Novo Nordisk Stock
Via Benzinga
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Via Benzinga
Is Novo Nordisk Gaining or Losing Market Support?
Via Benzinga
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Hims’ Weight Loss Expansion: Real Growth or Just Hype?
Via MarketBeat
Exposures Product Safety
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Government
Exposures Political
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound
Via Benzinga
Topics Government
Exposures Political
Retail Traders Prefer Novo Nordisk To Eli Lilly After Medicare Shuts Door On Obesity Drug Coverage — But There's More
Via Stocktwits
Topics Government World Trade
Exposures Political Tariff
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
Via Benzinga
Topics World Trade
Exposures Product Safety Tariff
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): good value for what you're paying.
Via Chartmill
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
Via Investor's Business Daily
Topics Government
Exposures Political
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Via The Motley Fool
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
Via Investor's Business Daily
Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales
Via Benzinga
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
Via Stocktwits
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Via The Motley Fool
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?
Via Benzinga
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
Via Investor's Business Daily
Exposures Product Safety

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 64.49
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 04/15/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.